RB1

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
Monday, March 25, 2024
Cloud, RB1, Hydrolysis, Irinotecan, Progression-free survival, Patient, SAN, Biomarker, Research, DNA, Cancer, Cmax, SN-38, Clinical trial, Curie Institute (Paris), Safety, Prodrug, Homologous recombination, ADC, TNBC, Teaching, PEG

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

Lantronix Introduces New Open-Q Family of SIP Modules That Deliver High-Performance for Mass Market Robotics and IoT Projects

Retrieved on: 
Tuesday, March 14, 2023
Robotics, Embedded, Linux, Intelligence, Internet of things, SOC, SIP, Qualcomm, RB2, Industrial, Automation, RB1, Yocto Project, Unmanned aerial vehicle, Arrow Electronics, Business development, AI, Video game, 3D printing

The SIP modules are powered by the Qualcomm® QRB2210 and Qualcomm® QRB4210 System-on-Chip (SoC) from Qualcomm Technologies Inc. Utilizing heterogeneous compute capabilities with multiple specialized processing cores, they deliver high-performance computing with lower power consumption.

Key Points: 
  • The SIP modules are powered by the Qualcomm® QRB2210 and Qualcomm® QRB4210 System-on-Chip (SoC) from Qualcomm Technologies Inc. Utilizing heterogeneous compute capabilities with multiple specialized processing cores, they deliver high-performance computing with lower power consumption.
  • Berg Insights forecasts that the three largest volume segments are floor-cleaning robots, UAVs and robot lawn mowers.
  • The Open-Q RB1 and RB2 Development Kits support the SIP modules for rapid prototyping of innovative new products.
  • It offers a full range of production-ready Edge AI computing solutions, including multi-disciplinary engineering services.

Thundercomm Launches its New SOMs TurboX C2210, C4210, C5430 at Embedded World 2023 to Accelerate Innovations in Robotics and Handheld Devices

Retrieved on: 
Wednesday, March 15, 2023
Robotics, Consumer Electronics, IOT (Internet of Things), Technology, Audio, Video, Artificial Intelligence, Hardware, SDK, Linux, Brain, TDK, Software, Ecosystem, Android, Internet of things, SOC, Product marketing, RB1, Tablet, Computing, Automation, Artificial intelligence of things, MIPI, SOM, Internet, Internet service provider, Marketing, AI, Consumer electronics, Qualcomm

The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.

Key Points: 
  • The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.
  • TurboX C4210 SOM is powered by the Qualcomm® QRB4210 SoC.
  • It features triple ISPs for advanced dual-camera experience, dedicated Compute DSP for computer vision and video post-processing.
  • TurboX C5430 SOM integrates the Qualcomm® QCS5430 SoC, a 6nm processor with superior performance, power efficiency, premium connectivity, and 3.5 TOPS computing power.

Kneron KL720 supports Qualcomm for virtually seamless AI for robotics, drones and industry 4.0

Retrieved on: 
Tuesday, March 14, 2023
SAN, Qualcomm, RB1, Robotics, FPS, Socs, Internet of things, Human, Foxconn, Language, Qualcomm Ventures, RB2, Automation, Computer data storage, Video game, Customer service, Sequoia

SAN DIEGO, March 14, 2023 /PRNewswire/ -- Leading edge AI solutions provider Kneron announces today that its KL720 AI SoC now supports the Qualcomm® Robotics RB1 and Qualcomm® Robotics RB2 Platforms from Qualcomm Technologies, Inc. for robotics, drones, and industry 4.0.

Key Points: 
  • SAN DIEGO, March 14, 2023 /PRNewswire/ -- Leading edge AI solutions provider Kneron announces today that its KL720 AI SoC now supports the Qualcomm® Robotics RB1 and Qualcomm® Robotics RB2 Platforms from Qualcomm Technologies, Inc. for robotics, drones, and industry 4.0.
  • Based in San Diego, Kneron is backed by the likes of Sequoia, Horizons Ventures, Qualcomm Ventures, and Foxconn.
  • For robotics use cases, the KL720 supports these Qualcomm Robotics RB1 and RB2 Platforms in deploying object detection for smart vacuum cleaners, customer service robots, as well as drones.
  • The combined solution of two Kneron KL720 chips paired with the Qualcomm® QRB2210 or Qualcomm® QRB4210 System-on-Chips (SoCs) that power the Qualcomm Robotics RB1 and RB2 Platforms respectively, can achieve up to four-fold increase in AI compute power compared to the Qualcomm Robotics RB2 Platform alone.

Kneron KL720 supports Qualcomm for virtually seamless AI for robotics, drones and industry 4.0

Retrieved on: 
Tuesday, March 14, 2023
SAN, Qualcomm, RB1, Robotics, FPS, Socs, Internet of things, Human, Foxconn, Language, Qualcomm Ventures, RB2, Automation, Computer data storage, Video game, Customer service, Sequoia

SAN DIEGO, March 14, 2023 /PRNewswire/ -- Leading edge AI solutions provider Kneron announces today that its KL720 AI SoC now supports the Qualcomm® Robotics RB1 and Qualcomm® Robotics RB2 Platforms from Qualcomm Technologies, Inc. for robotics, drones, and industry 4.0.

Key Points: 
  • SAN DIEGO, March 14, 2023 /PRNewswire/ -- Leading edge AI solutions provider Kneron announces today that its KL720 AI SoC now supports the Qualcomm® Robotics RB1 and Qualcomm® Robotics RB2 Platforms from Qualcomm Technologies, Inc. for robotics, drones, and industry 4.0.
  • Based in San Diego, Kneron is backed by the likes of Sequoia, Horizons Ventures, Qualcomm Ventures, and Foxconn.
  • For robotics use cases, the KL720 supports these Qualcomm Robotics RB1 and RB2 Platforms in deploying object detection for smart vacuum cleaners, customer service robots, as well as drones.
  • The combined solution of two Kneron KL720 chips paired with the Qualcomm® QRB2210 or Qualcomm® QRB4210 System-on-Chips (SoCs) that power the Qualcomm Robotics RB1 and RB2 Platforms respectively, can achieve up to four-fold increase in AI compute power compared to the Qualcomm Robotics RB2 Platform alone.

SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

Retrieved on: 
Wednesday, August 24, 2022
COVID-19, CDK9, IC50, Cancer, MYC, NASDAQ, Man, SLS, WT1, Memorial Sloan Kettering Cancer Center, Senior, SEC, NEPC, GPS, CRPC, Prostate, Acceleration, MD, GLOBE, Company, Therapy, RB1, TP53, Drug, Mutation, Terminology, Annual report, Prostate cancer, Drug development, Immortalised cell line, Patient, Pharmaceutical industry, Medical imaging, Greater China

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC). The data shows that GFH009 demonstrated significant anti-tumor effects in the selected cell line at nanomolar concentrations and, in certain samples, complete growth inhibition with no viable cancer cells.

Key Points: 
  • The data shows that GFH009 demonstrated significant anti-tumor effects in the selected cell line at nanomolar concentrations and, in certain samples, complete growth inhibition with no viable cancer cells.
  • NEPC, an aggressive variant of prostate cancer, is a rapidly growing indication which arises as a result of otherwise successful treatment of advanced prostate cancer.
  • In up to 15 to 20 percent of patients treated with hormonal therapies for prostate adenocarcinoma, small-cell prostate cancer may develop in later stages of prostate cancer progression.
  • Aggressive NEPC represents a lethal endpoint in the progression of prostate cancer from prostate adenocarcinoma to castration-resistant prostate cancer (CRPC) to NEPC.

SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

Retrieved on: 
Tuesday, August 9, 2022
Acute myeloid leukemia, Immortalised cell line, Survival, WT1, MYCN, Gene, BRCA1, GLOBE, Senior, NEW, Percentage, Drug, SEC, TP53, Annual report, AML, CDK9, Patient, NCI, Company, COVID-19, Acceleration, Therapy, Drug development, GPS, NASDAQ, Squamous cell carcinoma, RB1, Memorial Sloan Kettering Cancer Center, Ovarian cancer, MD, SLS, Adult, Terminology, Pharmaceutical industry, Vaccine, Greater China

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines. The data shows that GFH009 demonstrated significant anti-tumor effects in all four selected cell lines. In three out of the four cell lines, GFH009 inhibited cancer cell growth by 90 to 100 percent.

Key Points: 
  • - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90 to 100 Percent -
    NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc .
  • (NASDAQ: SLS) (SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines.
  • In three out of the four cell lines, GFH009 inhibited cancer cell growth by 90 to 100 percent.
  • NCI-H209: a small cell lung cancer cell line characterized by the loss of function of two major tumor suppressor genes, RB1 and TP53.

Paige AI Solution for Prostate Cancer Biomarker Detection Receives CE-IVD and UKCA Marks

Retrieved on: 
Thursday, May 12, 2022
Other Health, Research, Pharmaceutical, Oncology, Technology, Clinical Trials, Science, Biotechnology, Other Technology, FDA, Other Science, Health, Physician, Fluorescence, FISH, Memorial Sloan Kettering Cancer Center, Haematoxylin, Â, Research, MSK, Patient, Workflow, Immunohistochemistry, H&E, Oncology, FDA, Industry, In situ hybridization, Histology, Prostate cancer, Technology, Biomarker, Pathology, IHC, PTEN, UKCA, RB1, Diagnosis, Marie Cassidy, Tissue, TP53, Medical imaging

Paige , a global leader in clinical AI applications in pathology, today announced it received CE-IVD and UKCA marks for the Paige Prostate Biomarker Suite, an AI software that is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E)*.

Key Points: 
  • Paige , a global leader in clinical AI applications in pathology, today announced it received CE-IVD and UKCA marks for the Paige Prostate Biomarker Suite, an AI software that is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E)*.
  • Specifically, the Paige Prostate Biomarker Suite can detect biomarkers from H&E-stained samples and can inform the need for confirmatory tests such as immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).
  • The Paige Prostate Biomarker Suite is designed to assist in the detection of Androgen Receptor (AR), TP53, RB1 and PTEN biomarkers that are associated with the development and progression of prostate cancer.
  • *In the United States, Paige Prostate Biomarker Suite is available for Research Use Only and not for use in diagnostic procedures.

New Linea Provides Flexibility for Cultivators

Retrieved on: 
Wednesday, October 20, 2021
LED, RB1, Technology, OH, ROI, Greenhouse, IP66, Head, Horticulture, Industry, HPS, Agriculture

The new Linea is available in multiple spectrums including SpecGrade LED's A1 Entire Life Cycle and M1 spectrums.

Key Points: 
  • The new Linea is available in multiple spectrums including SpecGrade LED's A1 Entire Life Cycle and M1 spectrums.
  • "The new Linea takes everything we learned from its predecessor and improves upon it," says Doug Lauk, President of SpecGrade LED.
  • The new Linea Series meets that demand and also delivers flexibility not found with our competitors.
  • SpecGrade LED works with cultivators across North America providing cost-effective, energy-saving horticulture lighting solutions for cultivators.